SIOX Stock Overview
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Sio Gene Therapies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.48 |
| 52 Week High | US$0.50 |
| 52 Week Low | US$0.25 |
| Beta | 1.09 |
| 1 Month Change | 22.88% |
| 3 Month Change | 20.25% |
| 1 Year Change | 5.31% |
| 3 Year Change | -85.60% |
| 5 Year Change | -95.10% |
| Change since IPO | -99.73% |
Recent News & Updates
Can Sio Gene Therapies (NASDAQ:SIOX) Afford To Invest In Growth?
Oct 19
Here's Why We're A Bit Worried About Sio Gene Therapies' (NASDAQ:SIOX) Cash Burn Situation
Jun 27Recent updates
Can Sio Gene Therapies (NASDAQ:SIOX) Afford To Invest In Growth?
Oct 19Here's Why We're A Bit Worried About Sio Gene Therapies' (NASDAQ:SIOX) Cash Burn Situation
Jun 27My Favorite Stock For 2022: Sio Gene Therapies
Dec 27Sio Gene Therapies: Excellent Data And News Obscured By Officer's Departure
Oct 25We're Hopeful That Sio Gene Therapies (NASDAQ:SIOX) Will Use Its Cash Wisely
Sep 28Sio Gene Therapies EPS beats by $0.12
Jun 09Sio Gene Therapies: Gene Therapies For Neurodegeneration
May 28We Think Sio Gene Therapies (NASDAQ:SIOX) Needs To Drive Business Growth Carefully
May 07Have Insiders Been Buying Sio Gene Therapies, Inc. (NASDAQ:SIOX) Shares?
Mar 04Sio Gene Therapies secures $11.6M from sale of Arvelle Therapeutics
Feb 04What Is The Ownership Structure Like For Sio Gene Therapies, Inc. (NASDAQ:SIOX)?
Jan 28Sio Gene Therapies to sell Arvelle stake to Angelini Pharma
Jan 04Here's Why We're Watching Sio Gene Therapies' (NASDAQ:SIOX) Cash Burn Situation
Dec 24Sio Gene Therapies soars 45% on positive AXO-AAV-GM1 data in nerve cell disorder
Dec 16Did Sio Gene Therapies, Inc. (NASDAQ:SIOX) Insiders Buy Up More Shares?
Nov 19Axovant on go with pivotal study of gene therapy for rare inherited lipid disorders
Nov 09Axovant sees delayed enrollment in Parkinson’s study with gene therapy
Oct 29Shareholder Returns
| SIOX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 22.9% | -2.5% | -3.2% |
| 1Y | 5.3% | -3.7% | 19.3% |
Return vs Industry: SIOX underperformed the US Biotechs industry which returned 7.9% over the past year.
Return vs Market: SIOX underperformed the US Market which returned 17.5% over the past year.
Price Volatility
| SIOX volatility | |
|---|---|
| SIOX Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SIOX's share price has been volatile over the past 3 months.
Volatility Over Time: SIOX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 12 | David Nassif | www.siogtx.com |
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM.
Sio Gene Therapies Inc. Fundamentals Summary
| SIOX fundamental statistics | |
|---|---|
| Market cap | US$34.77m |
| Earnings (TTM) | -US$28.83m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs SIOX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SIOX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$28.83m |
| Earnings | -US$28.83m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SIOX perform over the long term?
See historical performance and comparison